Nova Diagnostics now offers collection service for IMBdx, a company committed to helping patients and physicians across the world fight against cancer, by liquid biopsy testing which is a minimally invasive test for cancer diagnosis using their unique technology and expertise.
Drop us a line!
If you have any enquiry, please do not hesitate to contact us.
Leave us a message and we will get back to you shortly.
In Nova Diagnostics, we offer collection service for the Blood-based liquid biopsy, a minimally invasive test for cancer diagnosis that requires a simple blood draw for IMBDX.
It has recently risen as a possible substitute for tissue biopsy which includes a surgical procedure to obtain a piece of tumor tissue for analysis. Please visit their website www.imbdx.com to find out more or contact us for more information.
The AlphaLiquid® series is a liquid biopsy platform that utilizes the most advanced tumor profiling technology along with Next Generation Sequencing, providing a comprehensive genomic solution for cancer patients.
AlphaLiquid® testing provides in-depth analysis of cancer-related genetic mutations within approximately 2 weeks from receiving the collected blood specimen. The resulting report assists healthcare professionals in making improved clinical decisions for progressive cancer patients.
The test offers a non-invasive and safer approach compared to tissue biopsy, and thus can be repeated whenever necessary. It can be applied for anticancer drug selection, recurrence monitoring, as well as early cancer detection in the near future.